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REVIEW
Intrauterine transfusion and non-invasive treatment options for hemolytic disease
of the fetus and newborn – review on current management and outcome
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ABSTRACT
Introduction: Hemolytic disease of the fetus and newborn (HDFN) remains a serious pregnancy
complication which can lead to severe fetal anemia, hydrops and perinatal death.
Areas covered: This review focusses on the current prenatal management, treatment with intrauterine
transfusion (IUT) and promising non-invasive treatment options for HDFN.
Expert commentary: IUTs are the cornerstone in prenatal management of HDFN and have significantly
improved perinatal outcome in the past decades. IUT is now a relatively safe procedure, however the
risk of complications is still high when performed early in the second trimester. Non-invasive manage-
ment using intravenous immunoglobulin may be a safe alternative and requires further investigation.
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Hemolytic disease of the fetus and newborn (HDFN) is still a
serious complication in pregnancy. The condition is caused by
maternal alloimmunization to fetal red cell antigens, inherited
from the father, leading to fetal hemolysis and anemia.
Untreated, progressing fetal anemia may result in hepatosple-
nomegaly, cardiomegaly, cardiac decompensation and even-
tually in fetal hydrops and perinatal death. If the fetus survives,
persistent hemolysis may lead to severe neonatal hyperbili-
rubinemia and brain injury, an irreversible condition known as
‘kernicterus’ [1]. Antibodies associated with severe HDFN are
mostly of the anti-Rh(D) type, and to a lesser extent of the
anti-Kell (anti-K1) or anti-Rh(c) type. Severe HDFN is occasion-
ally caused by other Rh-antibodies, and only very rarely by
non-Rh antibodies (Duffy, Kidd, or S) [2].
Prenatal screening for red cell antibodies and several pre-
ventive measures, such as matched blood transfusions for Rh-
and K antigens and the antenatal and postnatal administration
of anti-D immunoprophylaxis, have significantly reduced the
incidence and severity of HDFN [3,4]. Nowadays, approxi-
mately 1/300–1/600 pregnancies ending in live births are
complicated by red cell immunization [5].
If antibodies are detected in pregnancy, the risk of HDFN is
estimated using maternal serum testing for antibody levels
(quantification or titers) and, mainly in the Netherlands, anti-
body-dependent cell-mediated cytotoxicity (ADCC) assays for
RhD-immunizations [6–9]. In most countries, a critical titer
around 16, varying from 8 to 32, is used as a cut off for fetal
monitoring [8,10], although this value has a false-positive rate
of 77% for predicting fetal anemia [6].
Recent studies on antibody characteristics showed that
lower core fucosylation of RhD-antibodies significantly corre-
lated with increased disease severity [11] and in anti-c immu-
nizations, antibody galactosylation and sialylation best
predicted fetal/neonatal disease [12]. Furthermore, IgG1 anti-
D subtypes are associated with increased severity, in contrast
to IgG3 [13]. To our best knowledge, these interesting novel
insights are not yet implemented in general practice.
If either of these serum tests suggest an increased risk on
fetal hemolysis, the patient will be monitored by serial
Doppler measurements, as the peak systolic flow velocity
(PSV) of the middle cerebral artery (MCA) is considered the
most accurate noninvasive predictor of fetal anemia [14–19].
Until the 1960s, no prenatal treatment options for severe
HDFN were available. The only possible intervention in case of
suspected fetal anemia was to deliver the baby prematurely,
to enable neonatal treatment. HDFN was until then a major
cause of perinatal mortality. In 1963, Liley described the
intrauterine intraperitoneal blood transfusion (IPT), which con-
siderably reduced mortality rates [20]. However, the outcome
of fetuses with alloimmune anemia <26 weeks’ gestation and
of those with hydrops remained poor (32 and 42%, respec-
tively) [21]. In 1981, direct intravascular intrauterine transfu-
sions by fetoscopy (IUT) were first described [22], with initial
survival rates around 85% [23]. In the years that followed,
ultrasound guidance gradually replaced fetoscopy [24] and
since then, intravascular IUT has been the cornerstone of
treatment for fetal anemia due to red-cell alloimmunization
[22,23,25]. This review focusses on the current transfusion
techniques, complications and promising non-invasive treat-
ment options for HDFN.
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2. Prenatal treatment of HDFN
2.1. Intravascular intrauterine blood transfusion (IUT)
2.1.1. Transfusion preparation and details
2.1.1.1. Indication. IUT should be urgently performed if
MCA-PSV Doppler exceeds 1.5 multiples of the median
(MoM) and/or if signs of hydrops are present, as both corre-
late strongly with moderate to severe fetal anemia [5,16,17].
Timing of subsequent IUTs can be done by calculating the
expected decline in hematocrit and by MCA-PSV Doppler
measurements [26]. Nowadays, since the prediction using
the MCA Doppler is highly reliable, fetal blood sampling is
preferably directly followed by IUT and not performed as a
diagnostic tool without blood available for immediate trans-
fusion [27,28]. However, the degree of fetal anemia, assessed
by the hemoglobin concentration in the pre-transfusion fetal
blood sample, finally sets the conclusive IUT indication. The
cut offs used for this decision differ amongst the various
fetal therapy centers. However, authors agree that IUT
should only be performed in case of moderate to severe
anemia, usually defined as hemoglobin concentrations of
four to five standard deviations below mean/median for
gestational age [10,29–31] or a hemoglobin deficit of 5 g/
dL or more [32,33].
2.1.1.2. Setting. In the Leiden University Medical Center
(LUMC), the Dutch national referral center for fetal therapy,
the operating team performing IUTs is composed of a staff-
perinatologist, an experienced ultrasonographer and one or
two operating nurses [27]. This corresponds to the approach
of other centers, although in some centers an additional peri-
natologist or pediatrician is present [34–36].
Authors agree that IUTs need to be performed under asep-
tic conditions, guided by continuous ultrasound/Doppler,
using a 20–22 gauge needle [27,34,35,37,38]. No data are
available on the influence of needle size on procedure
complications.
2.1.1.3. Premedication. Maternal premedication varies from
local anesthetics only to routine indomethacin and/or pethi-
dine/promethazine to combined spinal epidural analgesia
[27,30,35], the latter being used to facilitate an emergency
caesarian section if needed. There is no expert uniformity or
scientific evidence supporting routine use of prophylactic anti-
biotics or corticosteroids [32,35,39,40] at IUT and these pro-
phylactic measures are not routinely used at our center [27].
Fetal premedication consists of an intramuscularly (or intra-
venously) administered paralytic agent and/or fetal pain med-
ication. Because of the reported lower risk of complications
following IUT when applying fetal paralysis in all cases, routine
use is advocated [27,29]. For fetal paralysis, atracurium
(0.4 mg/kg), vecuronium (0.1 mg/kg) or pancuronium
(0.1 mg/kg) are the most commonly used products [41–44].
Atracurium or vecuronium are often used as first-line preme-
dication option due to the fact that these short-lasting agents
give sufficient paralysis for IUT completion. Furthermore, pan-
curonium is associated with several cardiovascular side
effects [45].
As the neurologic basis for nociception is present from
24–28 weeks’ gestation and hormonal and circulatory stress
responses have been reported from as early as 18–20 weeks’,
fetal analgesia should be considered when performing inva-
sive fetal procedures [46]. Authors advocate 10 µg/kg fentanyl
to reduce the fetal stress response and possible fetal pain
sensation [46]. However, other authors have found that these
fetal hemodynamic and stress hormone changes are more
likely to be caused by volume expansion than by fetal stress,
as the response was independent of insertion site [47,48].
2.1.1.4. Transfusion volume. The transfusion volume is cal-
culated by the method described by Rodeck in 1984 [25],
making use of estimated fetoplacental volume (V), fetal hema-
tocrit in pre-transfusion sample (Ht1), donor blood hematocrit
(Ht2) and the aimed fetal hematocrit post-transfusion (Ht3):
Transfusion volume ¼ V Ht3  Ht1ð Þ=Ht2
Examples of used calculations for computing the fetopla-
cental volume (V) are:
● 0.1 mL volume/g of estimated fetal weight [49], or
● 0.15 mL volume/g of estimated fetal weight [50], or
● 1.046 + (fetal weight in grams) x 0.14 [51].
In order to simplify these formulas, Giannina et al. [49]
introduced a simplified equation and compared this to pre-
viously described methods [51,52]:
Transfusion volume = 0.02 × target increase in fetal Ht per
10% × g of estimated fetal weight,
assuming that donor blood hematocrit is approximately
75%. This equation was shown to be equally accurate as the
formula introduced by Rodeck and is therefore very useful as a
simplified calculation method for transfusion volume [25,49].
Target hematocrit should be around 45% [27,40,42,50,52].
Furthermore, fetal hemoglobin (Hb) testing prior to IUT is
nowadays often used to precisely calculate the volume to
transfuse.
2.1.1.5. Blood source. Intrauterine transfusions are usually
carried out with O-negative, washed, irradiated, leukocyte-
depleted blood, negative for the antigens against which the
mother is immunized [27,53]. In the Netherlands, donor blood
for IUTs is additionally matched with the maternal Duffy, Kidd
and S blood group, to reduce the high risk on the formation of
new antibodies [54]. Donations are usually from an allogenic
donor, as multiple maternal blood donations have been asso-
ciated with adverse pregnancy outcome [55,56], although a
direct cause–effect relation seems unlikely [57]. Altogether,
proposed advantages [41,53,57,58] usually do not outweigh
these possible adverse effects of autologous donations.
2.1.1.6. Simple vs. exchange. Intrauterine exchange transfu-
sion (IUET) has been proposed as an alternative to simple IUT
as exchange transfusions may result in a more stable hemato-
crit [59], potentially decrease the risks of (temporary) volume
overload and increase the interval between procedures.
However, the risk of procedure-related complications
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associated with IUETs may be higher, due to longer duration
and needle movements [60]. Furthermore, the excess volume
after simple IUT is thought to exit the intravascular compart-
ment, decreasing the risk of volume overload and fetuses
seem to tolerate single IUT quite well [61,62]. In a recent
(relatively small) cohort study in which IUT and IUET were
compared [34], no differences in benefits or complications
were found. However, data on the duration of the procedures
were not available. Nowadays, most fetal therapy centers opt
for simple transfusions rather than exchange transfusions.
2.1.2. Puncture site
Possible puncture sites or procedure access sites are: intrahe-
patic, placental cord insertion, transamniotic ‘free loop’ need-
ling, intraperitoneal and (exceptionally) sites as the fetal heart
of chorionic plate vein [29]. All transfusions should be aimed
intravenously, as arterial punctures are associated with high
complication rates [29,63]. The fetal liver and placental cord
insertion are shown to be the safest puncture sites, whereas
free loop needling is a higher risk procedure and should in our
view best be avoided [29,30,38–40].
Authors have postulated a beneficial effect of combined
intravascular and intraperitoneal transfusion on the inter-pro-
cedure interval [61]. In our center, the liver gained more and
more popularity as a puncture site in the last decades and
currently 57.1% of transfusions are performed intrahepatic,
frequently combined with intraperitoneal transfusion.
Analysis of the effect of this combined technique on transfu-
sion interval is planned. Our recent cohort study showed that
transplacental cord punctures were nowadays performed in
41.3% of procedures and a free loop of cord was the chosen
puncture site in only 1.1% of IUTs. In 0.5% of procedures,
blood was transfused intraperitoneally only [29].
2.1.3. Outcome
Many fetal therapy centers have reported on their IUT results
in recent years. Table 1 contains a summary of survival after
intravascular IUT from a selection of studies published in the
last 10 years.
Reported live birth rates after IUT vary from 88.9–100%
[29,30,36–40,64–66].
2.1.4. (Procedure-related) complications
Possible complications during or following IUT are: bleeding
from the puncture site, cord occlusion, brady- or tachycardia
and PPROM or preterm (emergency) delivery [63,64].
Furthermore, an intrauterine infection might be diagnosed
following any invasive procedure. These IUT complications
may lead to maternal morbidity, an emergency cesarean
section (CS) or even fetal death. We recently reported the
largest cohort study on procedure-related complications
after 1678 IUTs (741 unto 2000 and 937 from 2001 onwards)
[29]. We found a 1.2% procedure-related complication rate
per procedure in the new cohort (3.3% per fetus), compared
to 3.4% per procedure (9.8% per fetus) before 2001
(P = 0.003 and 0.001, respectively). In experienced hands,
1.8% of fetuses died as a direct result of the procedure,
indicating a 0.6% procedure-related fetal demise rate per
procedure. Refraining from fetal paralysis, arterial and free
loop needling were found to be important risk factors for
adverse outcome [29]. Furthermore, operators should per-
form at least 10 IUTs per year to retain their compe-
tence [67].
A summary of (procedure-related) complications in recent
studies is shown in Table 2 [29,30,37–40,64,65].
IUTs performed early in the second trimester, before
20–22 weeks of gestation, carry substantially higher risks on
(procedure-related) complications and fetal loss compared to
later IUTs, due to technical challenges of early procedures and
severity of disease. Reported survival rates for IUT series
started before 20–22 weeks lie around 76–88% [68–71].
Lindenburg et al. found a fourfold risk of perinatal death
after IUTs <20 weeks’ gestation, compared to IUTs later in
gestation [71].
To improve the perinatal outcome in this specific group
with fetal anemia early in the second trimester, several alter-
native strategies have been proposed. The intrahepatic trans-
fusion route is probably the preferred route, as the
surrounding tissue makes it easier to keep the needle in
place, despite the small vessel size in early pregnancy (<3–
5 mm before 20 weeks’ gestation) [38,50]. Some authors pro-
mote intraperitoneal transfusions instead [72] or noninvasive
treatment options to postpone early intravascular transfu-
sions [71].
Table 1. Overall survival after intrauterine transfusion.
Author, year N Hydrops (%) GA at first IUTa Technique Preferred puncture site Overall survival (%)
Somserset, 2006 221 26.9 25 (16–32) IUST Liver 90.9
Weisz, 2009 154 11.1 25.9 (3.2) IUET - 88.9
Tiblad, 2011 284 11.8 - IUST Liver 94.1
Johnstone-Ayliffe, 2012 114 13 26 (17–35) IUST Liver 93.5
Birchenall, 2013 256 - 30 (16–35.7) - Liver or PCI 95.3
Walsh, 2013 242 16 29.1 (19.2–34.4) - PCI 95.1
Pasman, 2015 135 14 - IUST PCI 100
Sainio, 2015 339 11.5 29 (18–36) - Free loop 96.2
Deka, 2016 303 21.6 26.9 (19.7–33.8) - PCI 96.1
Zwiers, 2016b 937 12.9 27 (16–36) IUST Liver 97
Overall 95.5
N: number of transfusions; GA: gestational age; IUT: intrauterine transfusion; overall survival: live birth rate; IUST: intrauterine single transfusion; IUET: intrauterine
exchange transfusion; PCI: placental cord insertion.
aweeks, median (range) or mean (range).
bresult of cohort since 2001 shown.
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2.2. Noninvasive options
Several noninvasive treatment options have been proposed to
postpone IUT in early severe HDFN, not as a sole treatment if
fetal anemia is already present [50].
2.2.1. Therapeutic plasma exchange (TPE)
In TPE, the patient’s plasma is removed and replaced with
albumin-rich fluid by passing the patient’s blood through a
cell separator [73]. The maternal antibodies directed
against fetal red cell antigens are then removed. TPE may
cause a decrease in antibody titers of as much as 75%,
resulting in a reduction of the risk of fetal hemolysis
[73,74]. However, the beneficial value of TPE alone to
postpone IUT in early severe HDFN was found to be dis-
appointing [50,71,73–75]. The deficiency of therapeutic
plasma exchange as a single treatment is possibly due to
a rebound effect, causing a rapid rise in antibody levels to
amounts equal as or higher than before TPE was per-
formed, even if TPE is continued [71,74].
Although the use of TPE is considered safe in pregnancy
[73], side and adverse effects do occur. For example, an
increase in antibody-dependent cell-mediated cytotoxicity
after TPE has been described, apart from the above-men-
tioned rebound phenomenon of antibody concentrations
[76]. Second, placental blood flow might be altered during
TPE, as fluctuations in pressure or electrolyte levels may cause
variations in maternal blood pressure. Furthermore, with
maternal serum extraction, coagulation factors and immuno-
globulin levels in maternal blood fall, causing increased risks
on postpartum hemorrhage and maternal and neonatal infec-
tions [75,77].
As all available knowledge regarding TPE for severe HDFN
is derived from observational case series, only category III
recommendations can be made and decision-making should
be individualized [73].
The decision to apply this technique for postponing an
early IUT could be made in cases with a history of severe
HDFN and should be individualized. Authors agree that, if at
all, it is best used combined with intravenous immunoglobu-
lins (IVIG), as described below [77,78].
2.2.2. Intravenous immunoglobulins (IVIG)
The effect of IVIG in HDFN may result from various mechan-
isms including (1) inhibition of Fc-mediated antibody passage
across the placenta, (2) negative feedback on maternal anti-
body production and/or (3) reticuloendothelial Fc-receptor
saturation/blockage, amongst others resulting in decreased
uptake of opsonized fetal cells by macrophages [74,79–83].
Although IVIG may prevent or reduce fetal hemolysis, it does
not treat fetal anemia [84].
In most fetal therapy centers applying IVIG, it is started at
400 mg/kg maternal weight/day for 5 consecutive days,
repeated every 2–3 weeks [80,82,84,85]. An alternative regime
could be 500 mg–1 g/kg maternal body weight weekly [78,86].
At our center, the first administration of IVIG is preferably
planned in the 12th week of pregnancy in an outpatient
setting usually at a dose of 500 mg/kg, followed by weekly
infusions of the same dose. These follow-up infusions are
offered as a home service by Sanquin Diagnostics, the national
blood and plasma product supply organization in the
Netherlands, reducing the burden of frequent hospital visits.
Few fetal therapy centers administrate IVIG directly to the
fetus after gaining intraperitoneal or intravascular access [87–
89]. The increased volume given to the fetus could lead to
cardiac compromise.
IVIG as a sole treatment to postpone early IUTs has shown
promising results in several case series [83,85]. The only pro-
spective study on maternal IVIG administration was performed
by Margulies et al. and reported on 24 severely Rh-sensitized
patients. In total, three fetal demises occurred (12.5%), in
hydropic fetuses. IVIG treatment caused a significant decline
in anti-D titers and hemolysis rate and even averted invasive
IUT in this severely affected group if started before 28 weeks’
gestation. Nevertheless, they concluded that for hydropic
fetuses and for fetuses with advanced fetal anemia, IUT is
inevitable [90]. In a retrospective study of the same group,
patients receiving IVIG before 20 weeks had significantly less
hydropic fetuses and a lower fetal mortality rate compared to
patients treated with IUT alone [84]. However, in another small
series of four cases of severe RhD-immunization, IVIG did not
seem to have any effect on transfusion frequency, maternal
antibody titers or hydrops [91].
Recently, a prospective case–control study in 34 women
compared IUT with fetal IVIG infusion to IUT alone and
described a slower hematocrit decline after IUT in the IVIG
group [89]. Similar results were found before, but no impact
on perinatal outcome was reported [87,88].
An occasionally used strategy is the combination of IVIG
and TPE. This treatment strategy is thought to oppose the
previously mentioned rebound effect of TPE alone and might
intensify the effect of IVIG and TPE on perinatal outcome.
Authors agree that this combined technique should be
reserved for the most severe cases. IVIG transfer to the fetus
in HDFN is thought to start from 10–12 weeks’ gestation,
supporting treatment schedules starting from this gestational
age [74]. A possible schedule could be: 3 serial TPE treatments
in the 12th week of pregnancy, followed by weekly IVIG
administration [78], although evidence for this schedule is
scarce [73]. The largest series reports on 9 severe HDFN









Somserset, 2006 67/221 - 2.1 -
Weisz, 2009 54/154 - 11.1 -
Tiblad, 2011 85/284 16.5/4.9 5.9 4.7/1.4
Johnstone-Ayliff,
2012
46/114 13/5.2 6.5 2.1/0.9
Pasman, 2015 56/135 3.6/1.5 0 0
Sainio, 2015 104/339 23.1/7.1 3.8 3.8/1.2
Deka, 2016 102/303 8.8/3 3.9 2.9/1.0
Zwiers, 2016b 334/937 3.3/1.2 3 1.8/0.6
Overall 848/2487 7.8/2.7 3.9 2.1/0.7
N: number of fetuses/transfusions; PR: procedure related.
PR complications: infection, PPROM or preterm delivery within 7 days, emer-
gency cesarean section, fetal loss.
aper fetus/per procedure.
bresult of cohort since 2001 shown.
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cases, in which a combined regimen of three TPE procedures
and weekly IVIG was used. Maternal antibody titers were
reduced, IUT seemed to be postponed and all babies were
alive and well at birth [78]. Several case reports have been
published with favorable outcome following this combined
approach [86,92–96].
Reported side effects of IVIG are rare but may include:
headache, fever, myalgia and low back pain, rush or chills,
urticaria, nausea and vomiting, tachycardia, chest tightness,
hypotension and shortness of breath [42,50,97,98]. These
events usually occur 30–60 min after admission and especially
the headache could be prevented by 1000 mg acetaminophen
before infusion [42]. Although very rare, renal failure, aseptic
meningitis, anaphylaxis (mainly in case of IgA deficiency),
hemolytic anemia, thromboembolism and pulmonary edema
are described [50,97,98].
Last, IVIG is an expensive treatment, with reported prices
around $6000/week [99]. The costs and benefits of IVIG should
be weighed against those of early IUT. Importantly, early IUT
may result in more complications, which also carries along
additional costs [71]. Furthermore, IVIG treatment might even
prevent perinatal deaths to occur, a situation associated with a
high psychological burden and of which the costs are difficult
to quantify.
Recommendations are based on observational studies only
and are therefore weak. However, there seems to be a bene-
ficial effect of IVIG (with or without TPE) to postpone early
transfusions and therefore it should be considered in patients
with a history of severe HDFN.
3. Expert commentary
In the past decades, improved prevention and screening stra-
tegies have greatly reduced the incidence of severe HDFN and
it is nowadays considered a rare disease. Consequently, yearly
IUT numbers per fetal therapy center decrease and centraliza-
tion of this highly specialized care becomes more and more
important. Fetal therapy centers from all over the world colla-
borate and invest in high-quality research to deliver the best
possible patient care in this field.
Not only did the incidence of HDFN decline, a dramatic
improvement in prognosis of HDFN was achieved. With the
introduction of intravascular IUTs and the availability of valu-
able noninvasive diagnostics for fetal anemia, survival
increased remarkably. Several adjustments in transfusion tech-
nique, such as transfusing through the intrahepatic vein or
placental cord insertion instead of using a free loop of cord
and applying routine fetal paralysis, have further improved
outcome.
Procedure-related complication rates are currently as low
as 3.3% per fetus and 1.2% per procedure in experienced
hands [29]. Nonetheless, preventable fetal losses do occur,
especially in fetuses in need for IUT before 20–22 weeks [71].
A truly evidence-based noninvasive approach to further
reduce fetal loss rates is however not yet available.
Nevertheless, the use of intravenous immunoglobulins to
postpone these hazardous early IUTs, potentially combined
with TPE, shows promising results in case series and single
center case-control studies [84,90]. Therapeutic plasma
exchange alone seems unable to create similar results.
4. Five-year view
Ideally a randomized controlled trial should be performed to
assess the efficacy and benefits of IVIG in the highest-risk
group of pregnancies complicated by HDFN. However, the
auspicious results of IVIG published so far has possibly made
it unethical to randomly assign patients with a history of
severe HDFN to a ‘non-IVIG’ study group. Therefore, an inter-
national multicenter cohort study on the effect of IVIG is
currently performed, in which IVIG cases are compared to a
reference group with similar disease severity but without IVIG
treatment. Depending on the results of this study, a rando-
mized trial could still be considered, taking above-mentioned
ethical dilemmas into account. If IVIG treatment proves to be
disappointing, other options such as stem cell treatment and
gene therapy will be investigated.
Key issues
● Although prophylaxis has strongly reduced the incidence of
maternal immunization against fetal red cell antigens,
HDFN is still a serious pregnancy complication which may
lead to severe fetal anemia, hydrops and perinatal death.
● Intravascular intrauterine transfusions are the cornerstone
in prenatal management and have significantly improved
perinatal outcome in the past decades.
● Several risk factors for adverse outcome after IUT have been
defined, such as refraining from fetal paralysis, arterial punc-
ture and free loop needling. Avoiding these hazardous tech-
nique causes continuously rising survival rates worldwide.
● Performing IUTs before 20–22 weeks’ gestation greatly
increases the risk on complications.
● The use of IVIG is an emerging non-invasive strategy to
postpone these early IUTs. More research is needed to
support its assets.
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